NCT00875264View on ClinicalTrials.gov

Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Cancer

Interventions

DRUG

CEP-11981 (kinase inhibitor)

Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.